Clinical Trials
Nectin-4, A Validated Target for Urothelial Cancer; Opening the Door for Novel Imaging and Therapeutic Development
We have had enfortumab vedotin for use in the clinic for patients with metastatic bladder cancer for many years now. The more recent FDA approval for enfortumab vedotin in combination with pembrolizumab on December 15, 20231 has yielded impressive results, essentially doubling the median overall survival for patients with previously untreated metastatic or locally advanced urothelial cancer.2
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Clinical Expertise
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.